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Background: Staphylococcus aureus bacteraemia is a common and serious infection, with an associated mortality of
~25%. Once in the blood, S. aureus can disseminate to infect almost any organ, but bones, joints and heart valves
are most frequently affected. Despite the infection’s severity, the evidence guiding optimal antibiotic therapy is
weak: fewer than 1,500 patients have been included in 16 randomised controlled trials investigating S. aureus
bacteraemia treatment. It is uncertain which antibiotics are most effective, their route of administration and
duration, and whether antibiotic combinations are better than single agents. We hypothesise that adjunctive
rifampicin, given in combination with a standard first-line antibiotic, will enhance killing of S. aureus early in the
treatment course, sterilise infected foci and blood faster, and thereby reduce the risk of dissemination, metastatic
infection and death. Our aim is to determine whether adjunctive rifampicin reduces all-cause mortality within
14 days and bacteriological failure or death within 12 weeks from randomisation.
Methods: We will perform a parallel group, randomised (1:1), blinded, placebo-controlled trial in NHS hospitals
across the UK. Adults (≥18 years) with S. aureus (meticillin-susceptible or resistant) grown from at least one blood
culture who have received ≤96 h of active antibiotic therapy for the current infection and do not have
contraindications to the use of rifampicin will be eligible for inclusion. Participants will be randomised to adjunctive
rifampicin (600-900mg/day; orally or intravenously) or placebo for the first 14 days of therapy in combination with
standard single-agent antibiotic therapy. The co-primary outcome measures will be all-cause mortality up to
14 days from randomisation and bacteriological failure/death (all-cause) up to 12 weeks from randomisation. 940
patients will be recruited, providing >80% power to detect 45% and 30% reductions in the two co-primary
endpoints of death by 14 days and bacteriological failure/death by 12 weeks respectively.
Discussion: This pragmatic trial addresses the long-standing hypothesis that adjunctive rifampicin improves
outcome from S. aureus bacteraemia through enhanced early bacterial killing. If proven correct, it will provide a
paradigm through which further improvements in outcome from S. aureus bacteraemia can be explored.
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Staphylococcus aureus bacteraemia (SAB) is one of the
most common serious bacterial infections worldwide. In
the UK alone there are more than 12,000 cases of SAB
each year and around 25% of these patients die [1,2].
Once S. aureus has entered the bloodstream it can dis-
seminate to cause metastatic infection of almost any
organ in the body. The sites most commonly affected
are the heart valves (5-10% of cases), joints (5% of cases),
intervertebral discs (5% of cases), bones (2% of cases)
and, less commonly, the brain, spleen and kidney.
Implanted prosthetic material, such as artificial heart
valves or joints, is at especially high risk of becoming
infected.
Current treatment guidelines recommend that SAB
should be treated with at least 14 days of an intravenous
(IV) beta-lactam antibiotic, or a glycopeptide if the bac-
teria are meticillin-resistant. Combination antimicrobial
therapy is generally not recommended, except in severe
meticillin-resistant S. aureus (MRSA) infections (e.g.
endocarditis, prosthetic joint infections) [3-6]. However,
the evidence supporting these recommendations is weak:
fewer than 1,500 patients have been entered in 16 rando-
mised controlled trials (RCT) of SAB antimicrobial ther-
apy published over the last 50 years [7]. Most of the
recommendations are based on uncontrolled observa-
tional studies and clinical experience, and views of how
to manage SAB differ widely [8,9].
How might adjunctive rifampicin improve outcome from
S. aureus bacteraemia?
The best clinical predictor of complications and death
from SAB is the persistence of bacteria in blood 48–96 h
after the start of active antimicrobial therapy [10-12].
Persistent bacteraemia (>48 h) occurs in around 40% of
patients, despite prompt removal of any infected focus
and effective antimicrobial therapy [10,11], and increases
the patient’s risk of metastatic complications and death
nearly five-fold [10]. Why S. aureus persists in blood
despite treatment with antibiotics with good in vitro ac-
tivity is uncertain, but is probably explained by the fail-
ure of currently recommended first-line antibiotics
(beta-lactams and glycopeptides) to kill bacteria asso-
ciated with pus (dead or dying neutrophils), viable cells
or biofilms. The well-documented survival of S. aureus
within each of these ecological niches may lead to per-
sistent bacterial seeding of the bloodstream and recur-
rent, recalcitrant infection. In addition, we have recently
proposed that bloodstream neutrophils may act as “Tro-
jan horses” for S. aureus dissemination, providing bac-
teria with further protection from first-line antibiotics
with poor intracellular activity such as the recommended
beta-lactams and glycopeptides [13].Three properties make rifampicin an attractive, if
unproven, adjuvant antibiotic for SAB treatment. First,
it has good oral bioavailability [14]. Second, it pene-
trates cells [15,16], tissues and biofilms [17,18] better
than beta-lactam and glycopeptide antibiotics [19,20]
(the current mainstays of SAB treatment) and, there-
fore, in combination with these agents, may resolve
serious S. aureus infections faster and more effectively
[18]. Third, it is cheap: a daily 600-mg dose costs
£0.73 by mouth and £7.67 intravenously [21]. Yet,
despite all these properties, the potential advantages
of adjunctive rifampicin for the treatment of severe S.
aureus infections in humans remain theoretical. There
are insufficient data from only 246 patients rando-
mised between rifampicin vs. non-rifampicin contain-
ing regimens in controlled trials to confirm or refute
a beneficial effect.
What are the potential problems of using adjunctive
rifampicin for S. aureus bacteraemia?
There are three important potential problems with using
rifampicin for the treatment of SAB: the development of
rifampicin-resistant bacteria, interactions with other
drugs and hepatic toxicity. Resistance can be acquired
rapidly when rifampicin is used alone in treatment,
resulting from mutations in the drug’s binding site (the
β-subunit of the bacterial DNA-dependent RNA poly-
merase). The frequency with which rifampicin resistance
develops during the combination therapy of SAB is diffi-
cult to assess from the published literature, varying from
0/433 patients treated with adjunctive rifampicin in
three non-randomised studies of serious S. aureus infec-
tions [22-24] to 20-40% of patients in other smaller case
series [25-27]. Interactions with other drugs are
mediated by rifampicin’s ability to increase their metab-
olism through the potent induction of the hepatic cyto-
chrome p450 system, but how frequently this influences
treatment outcomes is uncertain. Lastly, rifampicin can
cause hepatic toxicity, although the enormous worldwide
experience of using rifampicin for the prevention and 6-
month treatment of tuberculosis confirms the drug is
extremely well tolerated and causes clinically significant
hepatitis in <1% of patients [28].
Clinical evidence for using adjunctive rifampicin for S.
aureus bacteraemia
Four randomised controlled trials, involving 246
patients in total, have examined the effectiveness of
adjunctive rifampicin for serious S. aureus infections,
including patients with bacteraemia [29-32]. The first
two trials, published more than 25 years ago, enrolled
adults with any serious S. aureus infection, of whom
47/121 (39%) were bacteraemic at randomisation
[29,33]. The third trial enrolled 42 adults, all with SAB
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adults admitted to an intensive care unit with MRSA
pneumonia; only 9/83 (11%) were bacteraemic [32].
We performed a stratified meta-analysis of the results
from these trials (Figure 1); subgroup analysis of bac-
teraemic adults was possible for all but the fourth
trial, which did not provide sufficient data. Overall,
adjunctive rifampicin reduced infection-related deaths
by 55% (p = 0.02) and bacteriological failure by 58%
(p = 0.004), with similar (54%, 77%) but non-
significant (p = 0.22, p = 0.17) reductions in the bac-
teraemic subgroup (n = 89).Overall  (I - squared = 0.0%, p = 0.963) 
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Figure 1 Meta-analysis (fixed effects) of four trials of adjunctive rifamThe daily dose of rifampicin in these trials varied from
600 mg to 1,200 mg. Significant drug interactions were
not reported in any of the trials, and details concerning
hepatic toxicity were not provided in the first three
trials. The most recent trial reported 6/41 (15%) patients
treated with rifampicin developed hyperbilirubinaemia
(compared to 1 control patient) but the impact on treat-
ment was not described. This trial was also the only one
to report rifampicin resistance developing on treatment:
new resistance was found in 14/41 (34%) rifampicin-
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studies supporting the use of adjunctive rifampicin, al-
though, given the potential for confounding by indication,
their results must be interpreted cautiously. A prospective
study of 381 adults with SAB found the mortality of those
with severe disease was halved in those who received ad-
junctive rifampicin (mortality 38% vs. 17%, p < 0.001),
without an increased incidence of rifampicin resistance
[23]. A recent retrospective analysis of patients with
staphylococcal sternal wound infections, 35% of whom
had SAB, reported adjunctive rifampicin was independ-
ently associated with a reduced risk of treatment failure
(hazard ratio 0.26, 95% CI 0.10–0.64, p = 0.004) [24].
Current USA and UK guidelines only recommend ad-
junctive rifampicin for the treatment of severe MRSA
infections, specifically endocarditis, bone and joint infec-
tions, and infections involving prostheses (category II
evidence) [4,6]. But with weak support for these recom-
mendations it is unsurprising few UK physicians follow
them in practice [34]. In short, currently available evi-
dence suggests adjunctive rifampicin may substantially
improve the outcome from SAB but there are too few
data to balance the potential risks against the benefits.
We will, therefore, perform a large, multicentre, rando-
mised controlled trial with the aim of providing a defini-
tive answer to the question, ‘Does adjunctive rifampicin
improve outcome from SAB?’
Methods
Study hypothesis and objectives
We hypothesise that adjunctive rifampicin will enhance
killing of S. aureus early in the course of antibiotic treat-
ment, sterilise infected foci and blood faster, and thereby
reduce the risk of dissemination, metastatic infection
and death. Therefore, the primary objective of the trial is
to investigate the impact of adjunctive rifampicin on
both all-cause mortality through 14 days from random-
isation and bacteriological failure or death through
12 weeks from randomisation.
The trial’s secondary objectives include:
 assessing toxicity and emergence of resistance
associated with adjunctive rifampicin
 identifying the duration of bacteraemia and potential
mechanisms of action of rifampicin through
pharmacokinetic/pharmacodynamic (PK/PD)
investigations
 assessing the cost effectiveness of the use of
adjunctive rifampicin and other antibiotic therapy
for SAB in the UK NHS.
Study setting
The study will be performed in 17 large UK NHS Hos-
pital Trusts: Guy’s and St. Thomas’ Hospitals NHSFoundation Trust; Oxford University Hospitals NHS
Trust; University College London Hospital NHS Founda-
tion Trust; Royal Free Hampstead NHS Trust; Kings Col-
lege Hospital NHS Foundation Trust; Brighton and Sussex
University NHS Trust; Royal Liverpool and Broadgreen
University Hospitals NHS Trust; Sheffield Teaching Hos-
pitals NHS Foundation Trust; Cambridge University Hos-
pitals NHS Foundation Trust; Royal United Hospital Bath
NHS Trust; Royal Devon and Exeter NHS Foundation
Trust; Plymouth Hospitals NHS Trust; Hull and East
Yorkshire Hospitals NHS Trust; South Tees Hospitals
NHS Trust; Birmingham Heart of England NHS Founda-
tion Trust; St. Georges Healthcare NHS Trust; and Ports-
mouth Hospitals NHS Trust. Additional NHS centres may
be added after the start of the trial, if required.
Patient selection
Patients will be considered eligible for enrolment in this
trial if they fulfil all the inclusion criteria and none of
the exclusion criteria as defined below. Patients will be
identified through the clinical microbiology laboratory
and the infectious diseases/microbiology consult service
of each centre. All the trial centres run a clinical consult
service for all cases of SAB and identify such patients as
soon as their blood cultures become positive. The infec-
tious diseases physicians and microbiologists responsible
for this service will alert their colleagues responsible for
trial recruitment and they will arrange for the patient to
be seen and assessed for eligibility. All eligible patients
will be hospital inpatients. When possible, patients will
be screened for eligibility on the day their blood cultures
flags positive with S. aureus; this usually takes 24–48 h
from inoculation of the culture bottle.
Inclusion criteria
1. Adults (18 years or older)
2. S. aureus (meticillin-susceptible or resistant) grown
from at least one blood culture
3. Less than 96 h of active antibiotic therapy for the
current infection, not including rifampicin
4. Patient or legal representative (LR) provides written
informed consent
Exclusion criteria
1. Infection not caused by S. aureus alone in the
opinion of the infection specialist (e.g. S. aureus is
considered a blood culture contaminant or
polymicrobial culture with another organism likely to
be contributing clinically to the current infection)
2. Sensitivity results already available and demonstrate
rifampicin-resistant S. aureus (defined by British
Society for Antimicrobial Chemotherapy in vitro disc
susceptibility testing)
Thwaites et al. Trials 2012, 13:241 Page 5 of 14
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physician, considers rifampicin is contraindicated for
any reason
4. Infection specialist, in consultation with the treating
physician, considers rifampicin treatment is
mandatory for any reason
5. Infection specialist suspects active infection with
Mycobacterium tuberculosis
6. Previously been randomised in ARREST for a prior
episode of SABRandomisation
Eligibility will be confirmed by a web-based programme
and patients randomised to two parallel groups in a
1:1 ratio: standard intravenous antibiotic therapy plus
14 days placebo or standard intravenous antibiotic ther-
apy plus 14 days rifampicin. Randomisation will be
stratified by clinical site, as blinded drug (in fully made-
up and labelled treatment packs) will be pre-shipped to
local pharmacies. Randomisation lists will be computer-
generated based on random permuted blocks. A 24-h
web-based randomisation service will be provided.Treatment of patients
All patients will receive the standard of care antibiotic
to treat SAB that they would have received if they had
not been enrolled in the ARREST trial. In addition,
patients will be randomised to receive rifampicin or pla-
cebo (investigational medicinal product) as an extra
medication for 2 weeks (Figure 2). Rifampicin/placebo
for 14 days will be dispensed at randomisation from the
site pharmacy in oral (capsule) or intravenous formula-
tions, according to the attending physician’s preference
and the patient’s status. Rifampicin (300-mg capsules;
Sanofi Aventis Ltd., Surrey, UK) will be over-
encapsulated to make them indistinguishable from pla-
cebo. However, rifampicin for intravenous infusion
comes as a vial of red powder that requires reconstitu-
tion with 10 ml of water for infusion with saline. The
resulting fluid for intravenous infusion is orange. It is
impossible to safely and reliably produce a red-powder
placebo that will produce an identical orange infusion.
Therefore, we accept that the nurses making up the
intravenous drug for the infusion will not remain blind
to the treatment. They will be instructed not to divulge
the colour of the drug to the physicians caring for the
patient. In addition, the infusion will be covered by an
opaque bag to disguise the treatment.
The dose of rifampicin/placebo will be prescribed
according to the patient’s weight:
 those <60 kg will receive 600 mg every 24 h
 those >60 kg will receive 900 mg every 24 hOral rifampicin/placebo may be given once or twice
daily, according to physician preference. If 900 mg is
given twice daily, doses will be unequal (600 mg a.m.,
300 mg p.m.). The study treatment will be given for
14 days, unless fewer than 14 days of standard antibiotic
therapy is planned, in which case rifampicin/placebo will
be given until standard antibiotic treatment ends.
The choice and duration of the standard antibiotic
therapy that accompanies the rifampicin/placebo will be
left to the attending physician, but is expected to be ei-
ther a beta-lactam (e.g. flucloxacillin) or a glycopeptide
(vancomycin or teicoplanin). Daptomycin and linezolid
are the other alternatives, although current data from
the trial sites indicate <1% receive daptomycin and
around 5% receive linezolid as initial first-line therapy. A
pre-specified subgroup analysis will be conducted by
standard antibiotic therapy, at a class level, and accord-
ing to individual drugs where these are used by >10% of
the trial population. If the physician wishes to use other
antibiotics (or rifampicin) after 14 days (the study drug
duration), this will be open-label, but recorded.
Blinding issues
Rifampicin can turn urine (and tears/sweat) reddish-or-
ange. It is impossible to safely replicate this effect with a
placebo; therefore urine discolouration will be a poten-
tial source of unblinding, particularly of the patient.
There is, however, considerable inter- and intra-
individual variability in rifampicin’s effect on urine
colour. In some patients, the colouration is slight and
can be hard to distinguish from the dark, concentrated
urine frequently observed in acutely unwell patients. In
many, the orange urine colour becomes less marked
over time. In addition, the opportunity for physicians to
examine the urine at the bedside will only occur in
patients with urinary catheters. Catheters will not be
required by all patients and are usually removed at the
earliest opportunity. We will also limit the opportunity
for physicians to inspect urine by ensuring the catheter
bags are emptied regularly and urine it is not allowed to
accumulate in large volumes.
Assessments and follow-up
All participants will be followed by the site study teams
for 12 weeks for evaluation of all-cause mortality, mor-
bidity and toxicity. Subsequent follow-up will be elec-
tronic through hospital records (consent will be sought
for this together with consent for trial participation). To
assess the outcome measures, patients will be visited on
the ward by the site PI, one of their clinical team (e.g.
Specialist Registrar) or a research nurse on day 3, 7, 10
and 14 and then weekly whilst still in hospital through
12 weeks (see Table 1). All data will be recorded on
(electronic) eCRFs.
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Figure 2 Flow of participants through the trial.
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The trial’s co-primary outcomes will be:
 all-cause mortality up to 14 days
 death or microbiologically confirmed treatment
failure or disease recurrence (bacteriological failure)
up to 12 weeks from randomisation.
We have chosen these co-primary outcome measures
as they are both severe events and are thus unlikely to
be influenced by unintended unmasking of treatment
allocation (for example, through rifampicin discolour-
ing urine) and, if significantly reduced by rifampicin,
will provide an unequivocal stimulus to change
practice.Microbiologically confirmed treatment failure will be
defined as symptoms and signs of infection for longer
than 14 days from randomisation with the isolation of
same strain of S. aureus (confirmed by genotyping)
from a sterile site (e.g. blood, joint fluid, pus from
tissue). Disease recurrence will be defined as the iso-
lation of the same strain of S. aureus from a sterile
site after at least 7 days of apparent clinical improve-
ment. The same strain will be defined as one with
the same genotype by multi-locus sequence [35] and
spa-typing [36].
The secondary outcome measures will be:
 death or clinically defined treatment failure or
disease recurrence by 12 weeks (clinical failure being
T le 1 The ARREST trial assessment schedule
Day
Screening 0 1 2 3 5 7 10 Weekly until
discharged
84 Potential
failure/recurrence
A patients
E bility assessment X
P ent information sheet and consent X
R domisation X
C ical assessment(a) X X X X X X X
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E D X X X X
B d culture with sensitivities (10 ml)(c) (X) X X X X
E A blood(d) (1.5 ml) X
C ted blood(e) (5 ml)
C (X) X X X X
A , ALP, bilirubin (X) X X
S m storage X X
W le blood(f) (5 ml) X
S set of patients recruited to the intensive PK/PD substudy(g)
L ium heparin blood (3 × 3 ml/ time point) for antibiotic concentration assays(h) X X X
L ium heparin blood (10 ml) for compartment studies(i) X X X X X X X
C ted blood(e) (5 ml)
C X X X X X X X X
A , ALP, bilirubin X X
C tinine X X X
S m storage X X X X X X X X
B d culture (10 ml) X X X X X X X X
Thw
aites
et
al.Trials
2012,13:241
Page
7
of
14
http://w
w
w
.trialsjournal.com
/content/13/1/241ab
ll
ligi
ati
an
lin
eso
Q-5
loo
DT
lot
RP
LT
eru
ho
ub
ith
ith
lot
RP
LT
rea
eru
loo14
X
X
X
X
X
X
X
X
X
T e ARREST trial assessment schedule (Continued)
S tients recruited to the sparse PK/PD substudy(j)
L rin blood (3 × 3 ml in total) for antibiotic concentration assays(j) X X
C d(e) (5 ml)
C X X X
A rubin X X
C X
S e X X X
B (10 ml) X X X X X X
( ts that will have already been performed as part of standard management.
* as already been discharged from hospital before day 7, 10 or 14, additional investigations requiring a blood draw (culture, CRP, ALT, AL rum storage) are not required (patients should not be
a d outpatient appointments on these days, but to return at 12 weeks only).
( ikely source and focus of infection, co-morbidities, duration of symptoms, temperature and record of concomitant medications (includin dy antibiotics) at enrolment. Follow-up assessments
w w symptoms and signs indicating secondary site infections, all surgical interventions performed to treat the disease, grade 3 or 4 or ser vents, adverse events of any grade leading to
m f rifampicin/placebo dose or interruption/early discontinuation, any drug interactions leading to dose modification of any drug (includi nt medications) and all changes in antimicrobial
p
( used whilst in hospital will be recorded by health-care professionals (or any assigned representatives). These will include days spent in ures or laboratory tests undertaken and concomitant
m fter discharge, resource use will be self-reported by the patient. A data collection form will be developed that records post-discharge re ns and contact with clinicians (hospital, GP, etc.).
( res will have already been taken prior to the screening assessment from which the potential S. aureus bacteraemia will have been iden us isolated from blood cultures taken on days 0, 3 and
7 t least rifampicin susceptibility tests performed in order to evaluate the secondary endpoint acquisition of rifampicin resistance, althoug e routine panel of antimicrobial sensitivities will be
p l susceptibilities will be recorded). All S. aureus isolates to be stored locally, then shipped annually to central storage facility in Oxford an r biobanking. All repeat isolates will be genotyped to
d or re-infection. Blood cultures may be taken at any other time points necessary for clinical management of the patient. If these are con flect potential failure of treatment or recurrence, then
s ould be performed as above. Results of any additional blood cultures done should be recorded on ARREST CRFs, and S. aureus isolates ampicin susceptibility tested.
( rement of haemoglobin, white cell count, lymphocytes, neutrophils, platelets.
( rement of C-reactive protein (CRP), alanine transaminase (ALT), bilirubin and alkaline phosphatase (ALP) at time points shown. Serum cr nly be measured in the PK/PD substudies on days 0,
3 l of serum will be saved from clotted blood taken as shown, stored locally, then shipped to a central archive at King’s College London. function tests are routine investigations for patients
w d S. aureus bacteraemia, and results of pre-screening investigations should also be recorded on the screening CRF.
( EDTA and 2.5 ml into PAXgene blood RNA tube (Qiagen). Store EDTA blood for later DNA extraction and PAXgene tube for later RNA e ples will be stored locally before shipping to King’s
C n for DNA/RNA extraction and archiving if the patient has consented for human DNA/RNA storage.
( nts enrolled at Guy’s and St. Thomas’, University College London and Addenbrookes Hospitals will be approached.
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committee blind to the treatment allocation)
 duration of bacteraemia (blood cultures will be
taken on days 3 and 7 following randomisation)
 development of rifampicin-resistant S. aureus
 grade 3/4 adverse events
 serious adverse events
 modification of any treatment (including
concomitant medications) due to drug interactions.
 compliance with blinded rifampicin/placebo
 health-care-related costs of S. aureus bacteraemia
 EuroQol-5D questionnaire (EQ-5D)
Cause of death, microbiological and treatment failure/
recurrence will be adjudicated by an Endpoint Review
Committee (ERC) blinded to randomised allocations.
Safety
Rifampicin is given to around 9 million people each year
as the first-line, 6-month treatment of tuberculosis. It is
well tolerated and there is extensive experience amongst
all the trial centres investigators (infectious diseases phy-
sicians and microbiologists) of its safe use. Hepatitis is
the most important side effect of rifampicin: asymptom-
atic rises in liver transaminases occur in around 10% of
patients taking rifampicin and requires no action other
than careful monitoring. Significant rifampicin-induced
hepatitis [transaminases >5× the upper limit of normal
(ULN) +/− symptoms] is rare (<1% of patients) and usu-
ally resolves with discontinuation of the drug. The liver
function tests of patients will be routinely monitored
twice whilst taking the study drug (day 3 and day 10),
which is more frequent than recommended by UK
guidelines when using rifampicin to treat tuberculosis
[37]. However, the trial patients are likely to be more
acutely unwell than patients with tuberculosis and may
require closer monitoring; additional tests may be
requested at any time where necessary for patient man-
agement. Physicians will stop blinded rifampicin/placebo
(without unblinding) if in their opinion potentially
rifampicin-related severe hepatic toxicity occurs. Poten-
tially fatal hepatic injury is extremely unlikely given the
relatively short course of rifampicin, laboratory monitor-
ing and early withdrawal if the transaminases rise >5×
the upper limit of normal. The commonest side effect of
rifampicin is orange urine, but this effect is completely
harmless. Rifampicin also colours tears orange and can
stain contact lenses.
Rifampicin induces the hepatic metabolism of many
other drugs, which can result in their sub-therapeutic
concentrations. The recruiting infection specialists will
be responsible for identifying clinically important inter-
actions and ensuring appropriate action is taken to re-
duce the risks to patients; this may include judgingpatients receiving these medications as not eligible to
join ARREST.
All such adverse events will be reported on CRFs,
together with adverse events of any grade leading to
modification of the rifampicin/placebo dose or its
interruption/early discontinuation. All SAEs and SARs
should be notified to the MRC CTU within 24 h of
the investigator becoming aware of the event.
Sample size
Our current observational study data indicate 16% and
24% of all cases of SAB die by 14 days and 12 weeks
respectively. Data from Oxford (personal communica-
tions) suggest that a further 10% of patients have re-
peat isolation of S. aureus over the 12 weeks following
initial bacteraemia. Assuming 80% power, two-sided
alpha 0.025 (to adjust for multiple testing given 2 co-
primary endpoints) and a 10% loss to follow-up by 12
weeks, we would need to randomise 920 patients to
detect a 30% relative reduction in bacteriological fail-
ure/death from 35% to 25%, an absolute difference of
10% corresponding to an number needed to treat
(NNT) of 10. The meta-analysis of RCT data (Figure 1)
suggests adjunctive rifampicin reduced infection-
attributable death by around 50% in all patients with
serious S. aureus infections (relative risk 0.45, 95% CI
0.23 to 0.89), with a similar, albeit non-significant, ef-
fect in the subgroup with bacteraemia (relative risk
0.46, 95% CI 0.13-1.59). These findings strongly sup-
port a large effect size (40-50% relative reduction) in
mortality. Assuming 80% power, two-sided alpha 0.025
and a lower 4% loss to follow-up by 14 days (as most
patients will remain in hospital), we would need to
randomise 940 patients to detect a 45% relative reduc-
tion in mortality from 16% to 9%, an absolute differ-
ence of 7% and a NNT of 14. The total sample size is
therefore 940 patients. This provides 68% and 57%
power to detect smaller relative differences of 25% and
35% in bacteriological failure/death and death respect-
ively (other assumptions as above, alpha = 0.025). All
statistical tests of association in the analyses will be
interpreted with respect to a 0.025 rather than 0.05
threshold.
Statistical analysis
Rifampicin is hypothesised to be superior to standard of
care, and therefore the proposed analysis will be by
intention to treat, including all randomised patients with
all participants analysed according to the study group to
which they were randomised regardless of subsequent
treatment received. The co-primary endpoints (all-cause
mortality through 14 days, bacteriological failure/death
through 12 weeks) will be compared using time-to-event
methods (Kaplan-Meier plots and log-rank tests, Cox
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treatment failure/bacteriological failure/death. Duration
of bacteraemia will be compared using interval-
censored time-to-event methods. Patients not complet-
ing follow-up and not known to have died will be cen-
sored at their last contact in the primary analyses;
sensitivity analyses will assume all such patients were
alive at 12 weeks (i.e. assuming that vital status tracing
is robust and reliable). Primary analysis will not stratify
for site, as there may be some sites with no events
that would therefore not contribute to treatment
comparisons; secondary analysis will be conducted
stratified by site. Primary analysis will include all
randomised patients: secondary analysis will exclude
those (expected <1%) who are subsequently identified
as having rifampicin-resistant S. aureus on susceptibil-
ity testing. The frequency of serious, grade 3 and 4,
and drug-modifying adverse events will be tabulated by
body systems and by randomised groups, and the
groups will be compared using Fisher’s exact test.
Patients enrolled in the trial are likely to have het-
erogeneous underlying conditions (e.g. cardiac, dialysis,
cancer). However, precisely because the SAB will have
been acquired in addition to any underlying condition,
there is no a priori reason why rifampicin should be
more or less effective in any comorbid subgroup, other
than as a consequence of drug interactions with con-
comitant medications, which will be assessed as a sec-
ondary endpoint. Planned subgroups analyses will
therefore include time from initiation of antibiotics to
initiation of randomised treatment, time from random-
isation to initiation of randomised treatment, intended
oral randomised treatment frequency (once vs. twice
daily), initial treatment with oral study drug only or
regimen containing IV study drug, class of primary
antibiotic treatment, other antibiotic adjuncts (e.g. gen-
tamicin), MRSA/MSSA, IV catheter-associated infec-
tion/other, deep focus/no deep focus, endocarditis/no
endocarditis and age. An additional subgroup analysis
will be conducted splitting participants into terciles of
baseline C-reactive protein (CRP).
Cost-effectiveness analysis
We will conduct a cost-effectiveness analysis of therapy
for SAB in the NHS. This analysis will be informed by
the results of the trial. Due to the limited trial follow-
up period and the possibility of existing treatment
options other than those in the trial, we propose a
framework based on decision analysis. Such an ap-
proach allows including findings from the trial in the
context of the existing evidence on all treatments of
interest and is the preferred approach for societal deci-
sion making in the UK.Ethical issues
The trial complies with the principles of the Declaration
of Helsinki (2008). Written, informed consent will be
obtained from all patients, or their legal representatives
(LRs) if they lack capacity, before enrolment by the site
PI or an appropriately trained Consultant, Specialist
Registrar or Research Nurse. Patients (or their LRs)
would be free to withdraw from the trial at any time,
and this will be explicitly stated in patient information
sheets.
Incapacitated adults may be included in the trial as we
consider many of these adults will have the most severe
infection and therefore represent the group that might
stand most to gain from the enhanced anti-microbial ac-
tivity of rifampicin. We anticipate around 10% of
patients with S. aureus bacteraemia will be critically ill
and incapacitated on intensive care. In this circum-
stance, the site PI or another experienced and independ-
ent physician will follow the UK Mental Capacity Act
(2005) to formally assess the capacity of the individual to
make an informed decision to participate in the trial.
Once incapacity has been confirmed written informed
consent will be sought from either a personal (e.g. a rela-
tive) or a nominated LR (e.g. Consultant Intensivist car-
ing for the patient, but not involved in the trial). If the
subject regains capacity during treatment they will be
informed of the consent given by their LR and their
wishes respected concerning on-going participation. If
they are happy to remain in the trial, the patient should
complete a patient consent form at this time.
The trial protocol (V1.02) received national research
ethics committee approval in April 2012. Clinical Trials
Authorisation was granted by the Medicines and Health-
care products Regulatory Agency (MHRA) in May 2012.
Patient and public involvement
The ARREST trial has been developed with the
Healthcare-associated Infection Service Users Research
Forum (SURF: www.hcaisurf.org). A member of SURF
(Jennifer Bostock) will represent patients and the public
on the ARREST Trial Steering Committee. Ms Bostock
has advised on the inclusion of incapacitated adults and
the application of the Mental Capacity Act, and the in-
formation provided to patients. SURF will also help dis-
seminate the trial’s results beyond the academic and
health-care professional community to other patient
groups and the wider public.
Trial management and oversight
The Trial Management Group (TMG) will comprise the
trial team at the MRC CTU, plus the Chief Investigator,
the principal investigator at each site and the leads of
the integral substudies. A Trial Steering Committee
(TSC) with a majority of independent members will be
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Adrian Martineau and will also include an independent
microbiologist (Dr. Geoff Scott), an independent trialist
and infection specialist (Prof. Jeremy Farrar), and a pa-
tient representative from SURF (Mrs. Bostock). The CI
(Guy Thwaites) and two other site clinicians (Drs. Hop-
kins and Barlow) will also be formal voting members of
the TSC, although all site investigators may attend TSC
meetings as observers. The TSC will meet annually and
will have a TSC Charter agreed by all members before
the trial starts. The function of these committees and
their relationships are expressed in Figure 3.
An independent data-monitoring committee (DMC)
will be established to monitor the trial, reviewing trial
data on recruitment, safety, adherence to randomised
strategies and efficacy, as well as considering findings
from any other relevant studies. It will be chaired by
Prof. David Lalloo, an infectious diseases specialist, and
include an independent microbiologist (Prof. Mark
Wilcox), and an independent statistician (Prof. Doug
Altman).
Ancillary studies
There will be two ancillary studies to the main trial:
1. A population pharmacokinetic (PK) and
pharmacodynamic (PD) study of rifampicin,
flucloxacillin and vancomycin for the treatment of
S. aureus bacteraemia. Our aim is to determine
the pharmacological parameters of rifampicin,DMC: Data 
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Committee
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Clinical sites
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Figure 3 Trial organogram.flucloxacillin and vancomycin that best predict
treatment success and provide a rational basis
from which the optimal dose, frequency and route
of administration can be modelled statistically and/
or explored in future studies. Samples will be
taken without knowledge of randomised allocation,
although rifampicin concentrations will only be
measured in those receiving active drug. The
specimens will be batched and the assays
performed after every patient in the batch has
completed the trial; the laboratory team
performing the assays will only be given the
treatment codes for each batch of patients and
will perform them without knowledge of the
patients’ outcomes. No information about
rifampicin levels will be available outside the
laboratory team before the end of the trial,
although these results would be provided to the
trial Data Monitoring Committee.
2. The influence of host and bacterial genetics on
disease severity and outcome from S. aureus
bacteraemia. Our aim is to identify host and bacterial
genetic factors that influence disease severity (for
example, the development of metastatic
complications) and poor outcome from S. aureus
bacteraemia.
Funding
The main trial is supported by grant funding from the
National Institutes of Health Research (NIHR) Health & TSC 
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The ancillary studies are supported by local funding.
Discussion
The results of the meta-analysis of randomised con-
trolled trial data, together with the findings of observa-
tional studies, indicate adjunctive rifampicin may have a
surprising and substantial impact on survival from SAB.
These data do not, however, constitute evidence of suffi-
cient rigour to influence current treatment guidelines,
clinical practice or indeed the equipoise of clinicians
recruiting patients into the proposed trial – even clini-
cians in centres using rifampicin in a greater proportion
of patients have indicated their willingness to randomise
as they recognise the lack of evidence supporting their
practice. In particular, whilst statistically significant, the
results from the trial meta-analysis are not convincing as
they are based on a small number of patients in a small
number of trials over a wide period of time. In addition,
the potential negative impacts of rifampicin toxicity,
interactions and, in particular, resistance cannot be reli-
ably assessed in these studies. There is, therefore, clear
justification for a large randomised controlled trial of ad-
junctive rifampicin for SAB so that the potential benefits
of rifampicin can be evaluated directly and reliably
against the potential risks.
The trial addresses the hypothesis that early,
enhanced bacterial killing by rifampicin improves the
outcome from SAB. Two biomedical substudies are
therefore planned to understand the reasons why ad-
junctive rifampicin either works or fails to work, and
how bacterial and host genetic variation influences
clinical outcome; both provide the potential for perso-
nalising treatment in the future. Demonstrating
mechanisms underlying trial results has two major
impacts: first, saliency promotes uptake of positive trial
results into clinical practice and guidelines and pro-
vides reasons for clinicians to stop using ineffective
interventions; second, understanding such mechanisms
is critical to the rational choice of further interventions
to improve patient outcome. Such studies can be con-
ducted to a very high standard when integrated into a
large randomised controlled trial, substantially increas-
ing the value of the research.
One of the key considerations when designing this trial
was whether to perform an open label or blinded
placebo-controlled trial. The argument for an open trial
rests on two assumptions: first, it will be impossible to
blind patients and physicians, because taking rifampicin
turns urine orange, an effect that cannot be replicated
by placebo; second, knowing treatment allocation will
not matter if the primary endpoints are objectively
ascertained (e.g. death). An open trial, however, would
run a much higher risk that patients in the control armwould be managed differently than those in the rifampi-
cin arm. In particular, knowledge of the treatment allo-
cation may encourage the attending physicians to
prescribe other antibiotics (aminoglycosides, for ex-
ample) to those in the control arm perceived to be fail-
ing treatment. If this were to occur too often, the effect
of rifampicin could be obscured by the additional ther-
apy received in the control arm. In addition, physicians
may be tempted to investigate the treatment arms differ-
ently, perhaps having a lower threshold for ordering
radiological investigations in the control arm, changing
the likelihood that secondary complications and treat-
ment failure might be detected in these patients.
It is impossible to perform a true ‘double blind’
study using rifampicin, but we believe a blinded study
is preferable to an open study. We believe it will be
much harder for physicians to predict treatment allo-
cation than might otherwise be presumed. The placebo
cannot replicate the urine colouration, but its use will
mean treating clinicians will be uncertain of treatment
allocation and will, therefore, be much less likely to
manage patients differently in the respective treatment
arms. There is considerable inter- and intra-individual
variability in rifampicin’s effect on urine colour. In
some patients, the colouration is slight and can be
hard to distinguish from the dark, concentrated urine
frequently observed in acutely unwell patients. In
many, the orange urine colour becomes less marked
over time. In addition, the opportunity for physicians
to examine the urine at the bedside will only occur in
patients with urinary catheters. Catheters will not be
required by all patients and are usually removed at the
earliest opportunity. We will also limit the opportunity
for physicians to inspect urine by ensuring the catheter
bags are emptied regularly and urine it is not allowed
to accumulate in large volumes.
There is also an important sociological component
to the use of a placebo, which is particularly pertinent
in this trial because the patients’ primary physician is
likely to be a non-infection specialist (e.g. renal, car-
diothoracic). In an open trial, whether or not the pa-
tient is receiving rifampicin will be one of the first
questions that will be asked when patient management
is reviewed (when the infection specialist may not be
present) and it is very likely that subsequent manage-
ment will depend on the answer. Blinding, even if not
100% successful, sends a clear signal that whatever the
primary physician believes the patient might be receiv-
ing, this should not be taken into account in subse-
quent management.
Finally, the completed trial will stand alone as being
the first adequately powered randomised controlled trial
ever performed to address the optimal management of
SAB. The results will be scrutinised worldwide and
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within the NHS and beyond. An open trial may com-
promise the trial’s impact. If the results are negative,
critics may point to the possibility, detailed above, that
physicians treated control patients differently and rifam-
picin’s effect was disguised. Likewise, if the results are
positive some may question whether knowledge of the
treatment allocation led to enhanced care in the rifampi-
cin arm. It is important to foresee how the trial’s results
may be interpreted and we believe that an open label
trial may compromise the potential impact of the trial
and thereby limit the value of the research.
Trial status
The ARREST trial was conceived and designed by
members of the UKCIRG in 2010, with successful ap-
plication for peer-reviewed funding by the UK National
Institute for Health Research Health (NIHR) Health
Technology Assessment (HTA) Board in November
2011 (project no. 10/104/25). The trial will start re-
cruitment in December 2012 and will take 3 years to
complete; it will be managed through the Medical Re-
search Council Clinical Trials Unit (MRC CTU) in
London. The full version of the current trial protocol
is available at: http://www.ctu.mrc.ac.uk/research_areas/
study_details.aspx?s=262.
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